Lunes 22 de Abril 2019

Takeda Donates 1 Billion Yen as an Exclusive Partner to the United Nations Foundation for “Global Measles Vaccination for Children” Program

– Aiming at vaccinating 5.4 million children in approximately 40
developing countries –

OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TOKYO:4502)
today announced that Takeda will exclusively support “Global Measles
Vaccination for Children” by the United Nations Foundation’s Shot@Life
campaign. The initiative aims to provide measles vaccination to at least
5.4 million children in approximately 40 developing countries in Africa,
Asia, and Latin America over 10 years. We have donated one billion yen
to the United Nations Foundation to implement the program.

Measles is the one of the highest contagious diseases that killed nearly
115,000 children worldwide per year, which could have been prevented
with vaccination.* These deaths generally occurred in low-income
countries where there are many barriers to accessing vaccination. We
support activities to provide measles vaccination to at least 5.4
million children over 10 years from 2016 to 2026 in partnership with the
United Nations Foundation. In addition, opportunities to take a course
on vaccine and vaccination or for site visit will be provided to our
employees by the United Nations Foundation.

“Takeda is delighted to provide major funding to this important United
Nations Foundation initiative as an exclusive partner to give more than
5 million measles vaccines to children in developing countries around
the world,” said Haruhiko Hirate, Corporate Communications & Public
Affairs Officer. “We are at the center of many important vaccine-related
activities in global health and emerging infectious diseases, like
dengue, norovirus, polio and Zika, and also focusing on prevention for
health in developing and emerging countries through our global CSR
programs. This measles donation is yet another clear demonstration of
our commitment to the health of people everywhere.”

We have positioned vaccines as a core therapeutic area, and are actively
engaged in the development and sales of vaccines in response to the most
serious challenges in global public health. Given our 70-year-long
vaccine business in Japan, this program is considered to be closely
aligned with the business. We will contribute to better health and a
brighter healthcare future for people worldwide through leading
innovation in medicine as a pharmaceutical company involved in improving
people’s lives. Furthermore, we will also continue to contribute to
society by supporting patients who require more than just supply of
pharmaceutical goods, as well as their families.

In a new initiative, we have selected our global CSR program through a
vote by all employees. In 2016, three programs including this program,
“Community Health Workers Training for Maternal and Child Health
(Partner: World Vision),” and “Maternal and Newborn Health for Ethnic
Minority (Partner: Save the Children Japan)” which focused on maternal
and child health and released on the same day, have been selected.

* Source: WHO

About the United Nations Foundation

The United Nations Foundation builds public-private partnerships to
address the world’s most pressing problems, and broadens support for the
United Nations through advocacy and public outreach. Through innovative
campaigns and initiatives, the Foundation connects people, ideas, and
resources to help the UN solve global problems. The Foundation was
created in 1998 as a U.S. public charity by entrepreneur and
philanthropist Ted Turner and now is supported by philanthropic,
corporate, government, and individual donors. Learn more at:

About Shot@Life

Shot@Life, a campaign of the United Nations Foundation, educates,
connects and empowers individuals to champion global vaccines as one of
the most effective ways to save the lives of children in developing
countries. Go to
to learn more.

About Takeda CSR Activities

For Takeda, CSR is rooted in putting the patient in the center and
operating a pharmaceutical business that creates outstanding products.
In addition, we strive to maintain and improve sound business processes,
and to engage in activities to promote a sustainable society as a good
corporate citizen. In doing so, we are implementing a model of value
creation and preservation through CSR. This will help us to build trust
with society, reinforce our reputation, and further develop the
pharmaceutical business. For more information, visit

Takeda’s Commitment to Vaccines

Vaccines prevent more than two million deaths each year and have
transformed global public health. For 70 years, Takeda has supplied
vaccines to protect the health of people in Japan. Today, Takeda’s
global vaccine business is applying innovation to tackle some of the
world’s most challenging infectious diseases, such as dengue, norovirus
and polio. Our team brings an outstanding track record and a wealth of
knowledge in vaccine development, manufacturing and global access to
advance a pipeline of vaccines to address some of the world’s most
pressing public health needs.


Media Contacts:
Takeda Pharmaceutical Company Limited
Yoshikawa, +81 (0) 3-3278- 3004